BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32599988)

  • 21. Racial differences in three major NHL subtypes: descriptive epidemiology.
    Li Y; Wang Y; Wang Z; Yi D; Ma S
    Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study.
    Yu N; Zhang W; Zhong X; Song X; Li W
    PLoS One; 2024; 19(3):e0300330. PubMed ID: 38466704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia.
    Brewer JD; Shanafelt TD; Call TG; Cerhan JR; Roenigk RK; Weaver AL; Otley CC
    Int J Dermatol; 2015 Aug; 54(8):e287-93. PubMed ID: 25772131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reassessment of non-hodgkins's lymphoma with a "nodular" growth variant: a clinicopathologic study of follicular, mantle cell and marginal zone lymphomas prospectively diagnosed with multiparameter analyses.
    Kadowaki I; Ichinohasama R; Sasaki O; Kimura J; Kameoka JI; Meguro K; Endo K; Tobinai K; Sasaki T; Sawai T; Ooya K
    Leuk Lymphoma; 1998 Oct; 31(3-4):393-403. PubMed ID: 9869204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
    Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Ku FC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1995-2004. PubMed ID: 25971624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma.
    Ko YH; Kim CW; Park CS; Jang HK; Lee SS; Kim SH; Ree HJ; Lee JD; Kim SW; Huh JR
    Cancer; 1998 Aug; 83(4):806-12. PubMed ID: 9708949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies.
    Hernández-Molina G; Kostov B; Brito-Zerón P; Vissink A; Mandl T; Hinrichs AC; Quartuccio L; Baldini C; Seror R; Szántó A; Isenberg D; Gerli R; Nordmark G; Rasmussen A; Solans-Laque R; Hofauer B; Sène D; Pasoto SG; Rischmueller M; Praprotnik S; Gheita TA; Danda D; Armağan B; Suzuki Y; Valim V; Devauchelle-Pensec V; Retamozo S; Kvarnstrom M; Sebastian A; Atzeni F; Giacomelli R; Carsons SE; Kwok SK; Nakamura H; Fernandes Moça Trevisani V; Flores-Chávez A; Mariette X; Ramos-Casals M;
    Rheumatology (Oxford); 2022 Dec; 62(1):243-255. PubMed ID: 35385104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
    Hester LL; Park SI; Wood WA; Stürmer T; Brookhart MA; Lund JL
    Cancer; 2019 Apr; 125(7):1101-1112. PubMed ID: 30548238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.
    Lee SJ; Suh CW; Lee SI; Kim WS; Lee WS; Kim HJ; Choi CW; Kim JS; Shin HJ;
    Korean J Intern Med; 2014 May; 29(3):352-60. PubMed ID: 24851070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
    Baras N; Dahm S; Haberland J; Janz M; Emrich K; Kraywinkel K; Salama A
    Br J Haematol; 2017 Apr; 177(2):226-242. PubMed ID: 28106907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.
    Howlader N; Morton LM; Feuer EJ; Besson C; Engels EA
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):174-9. PubMed ID: 26472423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.
    Tadmor T; Liphshitz I; Silverman B; Polliack A
    Hematol Oncol; 2017 Dec; 35(4):599-607. PubMed ID: 27238496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second primary malignancies after ocular adnexal lymphoma diagnosis.
    Loya A; Ramachandran V; Ayaz T; Weng CY
    BMC Ophthalmol; 2021 Apr; 21(1):162. PubMed ID: 33827494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.
    Kane E; Painter D; Smith A; Crouch S; Oliver S; Patmore R; Roman E
    Cancer Epidemiol; 2019 Apr; 59():236-243. PubMed ID: 30844679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non Hodgkin lymphoma in Lebanon: a retrospective epidemiological study between 1984 and 2019.
    Touma E; Antoun L; Hallit S; Nasr F; Massoud M; El Othman R; Chahine G
    BMC Public Health; 2021 Oct; 21(1):1820. PubMed ID: 34627178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.
    Pizzi M; Trentin L; Visentin A; Saraggi D; Martini V; Guzzardo V; Righi S; Frezzato F; Piazza F; Sabattini E; Semenzato G; Rugge M
    Hum Pathol; 2019 Mar; 85():251-259. PubMed ID: 30458196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.
    Al-Hamadani M; Habermann TM; Cerhan JR; Macon WR; Maurer MJ; Go RS
    Am J Hematol; 2015 Sep; 90(9):790-5. PubMed ID: 26096944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cytogenetic and clinical study on 126 cases of B cell non-Hodgkin's lymphoma with bone marrow involvement].
    An G; Zhang JW; Shi LH; Yi SH; Zhao YZ; Qi JY; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):34-7. PubMed ID: 21429399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").
    Engels EA; Parsons R; Besson C; Morton LM; Enewold L; Ricker W; Yanik EL; Arem H; Austin AA; Pfeiffer RM
    Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1105-13. PubMed ID: 27197296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
    Akyurek N; Ren Y; Rassidakis GZ; Schlette EJ; Medeiros LJ
    Cancer; 2006 Oct; 107(8):1844-51. PubMed ID: 16983704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.